052020.KQ STCube, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
02:15
Feb 10
Feb 10
BTN1A1 drug targets PD-L1 non-responders
ST Cube is targeting BTN1A1 with nelmastobart to address patients who do not respond to PD-L1/PD-1 drugs such as Keytruda. Because BTN1A1 and PD-L1 are often expressed in a mutually exclusive way, the drug could expand the treatable immuno-oncology population; biomarker-based trials are underway, including non-small cell lung cancer from January and colorectal cancer, and success could trigger major partnership interest.
MED
02:14
Feb 10
Feb 10
ST Cube BTN1A1 immuno-oncology.
ST Cube targets BTN1A1 rather than PDL1, potentially addressing patients who do not respond to Keytruda and tumors where PDL1 is inactive. Early clinical data in NSCLC and colorectal cancer are the key catalyst.
MED
About 052020.KQ Investor Commentary
Across the available history and selected sources, Buzzberg tracks 052020.KQ (STCube, Inc.) across 1 sources: 0 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Noh Young-rae, Noh Young.